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EXPERT OPINION: PERIOPERATIVEThe cardiac surgery–associated neutrophil gelatinase-associated
lipocalin (CSA-NGAL) score: A potential tool to monitor acute
tubular damageHilde R. H. de Geus, MD, PhD,a Claudio Ronco, MD, PhD,b Michael Haase, MD, PhD,c
Laurent Jacob, MD, PhD,d Andrew Lewington, MD, PhD,e and Jean-Louis Vincent, MD, PhDfABSTRACT
Acute kidney injury (AKI), defined as a rise in serum creatinine (functional AKI),
is a frequent complication after cardiac surgery. The expression pattern of acute
tubular damage biomarkers such as neutrophil gelatinase–associated lipocalin
(NGAL) has been shown to precede functional AKI and, therefore, may be useful
to identify very early tubular damage. The term subclinical AKI represents acute
tubular damage in the absence of functional AKI (biomarker positivity without a
rise in serum creatinine) and affects hard outcome measures. This potentiates an
tubular-damage–based identification of renal injury, which may guide clinical
management, allowing for very early preventive-protective strategies. The
aim of this paper was to review the current available evidence on NGAL applica-
bility in adult cardiac surgery patients and combine this knowledgewith the expert
consensus of the authors to generate an NGAL based tubular damage score: The
cardiac surgery–associated NGAL Score (CSA-NGAL score). The CSA-NGAL
score might be the tool needed to improve awareness and enable interventions
to possibly modify these detrimental outcomes. In boldly doing so, it is intended
to introduce a different approach in study designs, which will undoubtedly expand
our knowledge and will hopefully move the AKI biomarker field forward. (J
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This paper introduces a biomarker based tubular
damage score that constitutes a key paradigm
shift in cardiac surgery-nephrology.Perspective
Identification of cardiac surgery–associated
tubular damage with the CSA-NGAL score
has the potential to aid the early diagnosis of
acute kidney injury. Thismight enable interven-
tions and therapies to reduce the incidence of
cardiac surgery–associated acute kidney injury.See Editorial Commentary page 1482.Worldwide, more than 2 million cardiac surgeries are per-
formed each year. Cardiac surgery–associated acute kidney
injury (CSA-AKI) is a serious postoperative complication,
and is the second most common cause of AKI in theintensive care unit.1 An incidence of CSA-AKI of up to
39% has been reported, varying depending on patient-
related baseline characteristics and the type of surgery.2
Between 3% and 6.5% of all surgical patients require renal
replacement therapy. This worst stage of CSA-AKI is
independently associated with a very high mortality rate.3
Other clinical consequences of CSA-AKI are increased
length of hospital stay, increased risk of chronic kidney
disease (CKD), and increased risk of death within 5 years
after surgery.4 The success of interventions or new
therapeutic strategies aimed at reducing the incidence of
CSA-AKI and its related outcomes depends on the optimum
time of their application, which is at the very early stages
of AKI.DIAGNOSIS OF FUNCTIONAL AKI
To create uniformity in the diagnosis of AKI, the RIFLE
(risk of renal injury/injury to the kidney/failure of kidney
function/loss of kidney function/end-stage disease) criteria
were proposed in 2004,5 followed by the Acute Kidney
Abbreviations and Acronyms
AKI ¼ acute kidney injury
AKIN ¼ Acute Kidney Injury Network
CKD ¼ chronic kidney disease
CSA ¼ cardiac surgery associated
eGFR ¼ estimated glomerular filtration rate
KDIGO ¼ Kidney Disease–Improving Global
Outcomes
NGAL ¼ neutrophil gelatinase-associated lipocalin
RIFLE ¼ risk of renal injury/injury to the kidney/
failure of kidney function/loss of kidney
function/end-stage disease
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de Geus et al Expert Opinion: PerioperativeInjury Network (AKIN) criteria in 20076 and the Kidney
Disease–Improving Global Outcomes (KDIGO) criteria in
2012.7 These criteria express the deterioration of kidney
function as a decline in the estimated glomerular filtration
rate (eGFR), which is based on an increasing serum creati-
nine (SCr) concentration and a declining urine output. How-
ever, in health, the kidneys have a significant degree of
excess capacity, such that 50% of the functional kidney
mass can be damaged without any drop in SCr-based
eGFR. Therefore, an increase in SCr occurs relatively late
after the initial injurious event (24-48 hours), with hemodi-
lution related to pump priming as an additional contributor
to this delay.
In view of this limitation of an SCr-based definition of
AKI, an additional test indicating that assessment of acute
tubular damage might be of value for the clinician. The
idea that detection of this so-called ‘‘subclinical AKI’’8
(ie, acute tubular damage in absence of an elevated SCr con-
centration) was recently suggested by the Acute Dialysis
Quality Initiative (ADQI)-10 consensus work group.9 The
field of AKI biomarkers is rapidly evolving, and new pro-
teins released by injured tubular cells are constantly being
discovered. All of these new biomarkers carry the potential
to serve as markers for acute tubular damage in the absence
of functional AKI. Neutrophil gelatinase-associated lipoca-
lin (NGAL) is the most well described and studied AKI
biomarker in adult patients undergoing cardiac surgery to
date, and is our current focus of interest.NGAL
NGAL is a small siderophoric protein that is intensely up-
regulated and excreted in cases of acute tubular damage. It can
be detected in both plasma and urine. In the early phases of
AKI, NGAL mitigates iron-mediated toxicity by providing a
reservoir for excess iron, and in subsequent phases, it pro-
motes regeneration and repair by regulating intracellular
iron availability. NGAL is readily filtered in the glomerulus
and readily reabsorbed in the proximal tubular segments.The Journal of Thoracic and CarImmediately following diverse injurious events, NGAL is
up-regulated in the distal parts of the nephron. Consequently,
increased levels of plasma and urinary NGAL are detectable,
presumably resulting from both apical and basolateral secre-
tion. Impaired proximal tubular reabsorption, due to coexist-
ing or subsequent proximal cellular damage that exceeds the
megalin-dependent transport maximum, further potentiates
urinary NGAL excretion.10,11 Although other sources of
NGAL exist in various pathological states (ie, inflammation,
infection, intoxication, ischemia, and neoplastic formation),
a potentiated NGAL response is very discriminative for
acute tubular damage, as confirmed by experiments in
NGAL-knockout mouse models.12DIAGNOSIS OF ACUTE TUBULAR DAMAGE, OR
SUBCLINICAL AKI
Based on the results of a multicenter pooled analysis by
Haase et al8 on the clinical impact of subclinical AKI, defined
asNGALexpression in absence of functionalAKI, a clear sep-
aration in the definition between acute tubular damage and
functional AKI seems justified. Acute tubular damage is a
pathological process that is separated in time (earlier) from
SCr-based dysfunction, which is not always manifested as
AKI according to the RIFLE, AKIN, and KDIGO definitions.
Nonetheless, the independent presence of acute tubular dam-
age affects patient outcomes and thus should at least be recog-
nized and possibly addressed as a separate clinical entity.8We
propose the use of NGAL as the biomarker in a new definition
of acute tubular damage, the Cardiac Surgery–Associated
NGAL (CSA-NGAL) score to further complement the func-
tional diagnosis of AKI.A PROPOSAL: USE OF THE CSA-NGAL SCORE TO
DETECTACUTE TUBULAR DAMAGE
The CSA-NGAL score (Figure 1) was created by
H.R.H.d.G., C.R., M.H., L.J., A.L., and J.-L.V., all experts
in the field of critical care and critical care nephrology, after
round table discussions. Although the urge to move the field
of kidney biomarker research to a different level has been
present for awhile, the lack of definite threshold values
for biomarkers such as NGAL and a scoring system linked
to treatment suggestions has hindered the development of a
new scientific approach.
Today, the level of evidence regarding NGAL cutoff
values for the detection of acute tubular damage is much
higher than that available at the time of the introduction
of the RIFLE criteria, which were based on potentially
prognostically relevant and memorable SCr cutoff values.
Results supporting the prognostic significance of the RIFLE
criteria were reported subsequently.13,14 We propose that
the introduction of applicable NGAL cutoff values in the
CSA-NGAL score will result in a similar development for
the diagnosis of subclinical AKI.diovascular Surgery c Volume 151, Number 6 1477
FIGURE 1. CSA-NGAL score. CSA, Cardiac surgery associated; DNGAL, NGAL increase; CSA-NGAL score, cardiac surgery–associated NGAL score;
uNGAL, urine NGAL; pNGAL, plasma NGAL.
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Based on the published observational data and our per-
sonal experience, we have suggested potential thresholds
to enable standardized research, which remain to be vali-
dated in prospective studies. We did this based on the
assumption that it has little foreseeable clinical downside.15
The absolute threshold recommendations for the NGAL
cutoff values are based on published values measured using
available clinical platforms, including the NGALTest (Bio-
Porto Diagnostics, Gentofte, Denmark), Triage (Alere,Wal-
tham, Mass), and ARCHITECT (Abbott Diagnostics, Lake
Forest, Ill). Accordingly, the 95th percentile of NGAL con-
centration in healthy persons provided by the platformman-
ufacturers was considered.
For application in clinical research protocols, standard-
ized laboratory platforms are needed to enable generalize
ability and comparability of future studies. Acute tubular
damage occurs in a continuum, and absolute cutoff values
of 150 ng/mL for urinary NGAL and 200 ng/mL for plasma
NGAL are reasonable for identifying patients with acute
tubular damage related to cardiac surgery or critical
illness16-21 (Figure 1). Such acute tubular damage is associ-
ated with a risk of de novo AKI, progression of established
AKI, poor recovery of renal function, increased need for
initiation of renal replacement therapy, and development
of CKD, end-stage renal disease, and eventually death.
Delta values should be considered in patients with changes
in NGAL concentration in sequential measurements, espe-
cially in patients in whom the absolute NGAL value does
not exceed the suggested threshold, as well as in patients
with preoperative renal impairment.19 Therefore, it is sug-
gested that increases in urine NGAL concentration
>100 ng/mL with the second value 125 ng/mL and in1478 The Journal of Thoracic and Cardiovascular Surplasma NGAL concentration>100 ng/mL with the second
value 150 ng/mL are indicative of acute tubular damage
(Figure 1).
HOWTO INTERPRET NGALVALUES IN CASES OF
PREOPERATIVE RENAL IMPAIRMENT?
Preoperative renal impairment, defined as an eGFR
<60mL/min/1.73m2, proteinuriawith>30mg/g creatinine,
or a dipstick analysis result >1þ, might contribute to
elevated plasma NGAL baseline values (209 ng/mL in pa-
tients with AKI vs 120 ng/mL in those without AKI).19
Thus, knowledge of a patient’s baseline NGAL value is
needed for the subsequent interpretation of values measured
during or immediately after surgery. This necessitates the in-
clusion of delta (D) NGAL concentration in the CSA-NGAL
score (Figure 1), as well as determination of a preprocedure
baseline NGAL value. In contrast, Perrotti et al22 reported a
6-hour plasma NGAL cutoff value of 155 ng/mL for the
presence of AKI in patients with a preoperative creatinine
clearance <60 mL/min/1.73 m2. Several other studies
have reported essentially unchanged cutoff values for AKI
as well, even in the presence of preexisting CKD.17,18 At
this time, the evidence regarding the impact of renal
impairment is at least conflicting, and thus we recommend
applying the proposed DNGAL thresholds prospectively
to generate the data to address these uncertainties.
CSA-NGAL SCORE: POSSIBLE CLINICAL
IMPLICATIONS
In current medical practice, patients experience multiple
subclinical episodes of acute tubular damage. After cardiac
surgery, patients are routinely prescribed diuretics,
angiotensin-converting anzyme inhibitors and antibiotics,gery c June 2016
FIGURE 2. CSA-NGAL Score clinical decision algorithm. CSA-NGAL score, Cardiac surgery–associated NGAL score; NGAL, neutrophil gelatinase-
associated lipocalin; Tb, baseline; RRT, renal replacement therapy; ICU, intensive care unit; TDn, day postsurgery; DNGAL, NGAL increase; uNGAL, urine
NGAL; pNGAL, plasma NGAL; EDTA, ethylenediaminetetraacetic acid.
de Geus et al Expert Opinion: Perioperativeas required, potentially adding additional insults to
undetected acute tubular damage. Application of the
CSA-NGAL score can prevent this scenario. A structured
preoperative risk assessment to assess a patient population
at high risk for AKI is desirable as well.23 Baseline mea-
surements can aid in preoperative risk assessment, and
elevated NGAL values may even suggest postponing sur-
gery until kidney function can be optimized and additional
insults avoided18,24 (Figures 2 and 3). This concept is sup-
ported by the findings of Di Somma and colleagues,20
who reported improved prognostication of kidney damage
and overall related outcomes when NGAL measurements
were added to the clinical assessment. Prospective observa-
tional and intervention studies are needed to apply theThe Journal of Thoracic and CarCSA-NGAL score as a clinical tool to enable a more precise
estimation of the incidence and impact of subclinical AKI.
In our view, this is the only way to answer the questions of
whether routine use of NGAL as a biomarker can offer addi-
tional value in patient care, which is the only way to push
AKI-related biomarker research to the next level.
SEQUENTIAL MEASUREMENTS
The dynamics of NGAL in patients undergoing cardiac
surgery have been carefully documented over the past
decade. A clear relationship is evident between pump run
and acute tubular damage; therefore, the temporal assess-
ment of biomarkers is likely to have value for clarifying
prognostic uncertainty. Based on the available evidence,diovascular Surgery c Volume 151, Number 6 1479
FIGURE 3. Clinical management considerations in patients admitted for cardiac surgery.CSA-NGAL score, Cardiac surgery–associatedNGAL score;AKI,
acute kidney injury;NGAL, neutrophil gelatinase-associated lipocalin; SvO2, central venous oxygen saturation; ICU, intensive care unit; RRT, renal replace-
ment therapy.
Expert Opinion: Perioperative de Geus et althe optimal times for NGAL measurements are the day
before surgery, during surgery, and the day after surgery.
The baseline urine or plasma value would be presurgery
(within 24 hours before the procedure), following by values
obtained at 4 to 6 hours after the commencement of surgery
(knife to skin) and at day 1 postsurgery (within 6-12 hours
after returning to the intensive care unit).
ADDITION OF THE CSA-NGAL SCORE TO RIFLE,
AKIN, OR KDIGO SCORES
The CSA-NGAL score has the capability of identifying
tubular damage in patients not yet displaying clinical
dysfunction (RIFLE stages R-F, AKIN stages 1-3, or
KDIGO stages 1-3). This early detection of acute tubular
damage preceding functional loss could trigger appropriate
therapeutic modifications (Figure 3). Furthermore, the
CSA-NGAL score can help rule out acute tubular damage
in patients with preexisting chronic dysfunction (elevated
SCr, no rise in NGAL) or in patients experiencing a simple
functional adaptation to hypovolemia without acute tubular
damage (elevated SCr, no rise in NGAL).
URINE OR PLASMA NGAL?
The current evidence shows no superiority of urine
NGAL over plasma NGAL measurements or vice versa in
AKI predictive ability, and thus either may be used1480 The Journal of Thoracic and Cardiovascular Suraccording to hospital preference and availability. Switching
between urine and plasma measurements is not advisable,
however, given some baseline and range differences.
PERSPECTIVE
Wepropose the application of theCSA-NGALscore in pro-
spective studies with adults undergoing cardiac surgery in
addition to a functional score for AKI (RIFLE, AKIN or
KDIGO). Acute tubular damage without functional AKI (ie,
subclinical AKI) affects hard outcome measures, and the
recognition of its presence has the potential to facilitate the
earlier implementation of interventions or precautions to pre-
vent further damage and/or progression to functional AKI.
The prevalence of functional AKI is estimated to be
considerably higher than previously thought, with 80% of
cases not captured in routine hospital data.25 The conse-
quential economic impact of this estimate in terms of excess
inpatient deaths and associated morbidity is huge and jus-
tifies increased awareness of the disease, including the clin-
ical signs that may precede it.25 The CSA-NGAL score
might be the tool needed to improve awareness of acute
tubular damage, which will allow for early interventions
to possibly modify these detrimental outcomes.
Although use of the CSA-NGAL score might be chal-
lenging and bold based on the available literature, we
believe that there is an urgent need to do so. In our view,gery c June 2016
de Geus et al Expert Opinion: Perioperativefurther biomarker studies that will show slight area under
the curve improvements and slightly different optimal cut-
off values in the prediction of CSA-AKI will not add any
new insights. Moving forward from what we already
know will require changing clinicians’ mindset, as well as
the approach to study design. In boldly doing so, we will
expand our knowledge of biomarkers and assess the pros-
pects of further progression in the field. An early diagnosis
of acute tubular damage might increase the effectiveness of
therapies and interventions. The CSA-NGAL score will un-
doubtedly need to be reevaluated and refined in the near
future as new data become available.
In conclusion, we have constructed a bridge between sci-
ence and a possible clinical application for NGAL. It is time
to recognize that for a defined patient population at high risk
for procedure-related functional AKI, acute tubular damage
may occur before dysfunction becomes apparent. This sub-
clinical AKI is a separate entity that should trigger aware-
ness and clinical interventions. The measurement of
NGAL in this setting will act to support other available clin-
ical information in patient management and generate pro-
spective knowledge of a different level than that currently
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